BOTHELL, Wash. (AP) ¿ Development-stage biotechnology company Seattle Genetics Inc. said Thursday its third-quarter loss narrowed on higher revenue from partnerships.

The company lost $19.8 million, or 21 cents per share, compared with a loss of $21.8 million, or 27 cents per share, during the same period a year prior. Revenue rose 44 percent to $11.6 million from $8.1 million.

Analysts polled by Thomson Reuters expected a loss of 25 cents per share on revenue of $9.4 million.

The company's key partnership is with Genentech Inc., now part of Roche. The companies are developing potential cancer treatments.

Shares of Seattle Genetics rose 12 cents to close at $9.85.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Technology

Should You Invest In Uber or Lyft's IPOs Next Year? Try Neither

Should You Invest In Uber or Lyft's IPOs Next Year? Try Neither

Tencent Music's IPO Is Priced at Low-End of Range in Downsized Debut

Tencent Music's IPO Is Priced at Low-End of Range in Downsized Debut

Facebook's Search Test Is a Reminder of Its Untapped Revenue Potential

Facebook's Search Test Is a Reminder of Its Untapped Revenue Potential

Here Are the 8 Biggest Tech IPOs to Watch For in 2019

Here Are the 8 Biggest Tech IPOs to Watch For in 2019

5 Highly Anticipated Tech IPOs to Watch in 2019

5 Highly Anticipated Tech IPOs to Watch in 2019